Dioptre

Vuzix Expands Its Market Leadership in Optical Waveguides with the Addition of Integrated Vision Correction Prescriptions

Retrieved on: 
Tuesday, January 30, 2024
OEM, Moscone Center, Prescription, Dioptre, Longevity, FDA, Smartglasses, Augmented reality, Privacy, HMD

ROCHESTER, N.Y., Jan. 30, 2024 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of smart glasses and Augmented Reality (AR) technology and products, announced it now has the ability to supply optical waveguides with integrated vision correction prescriptions, further expanding the applicability for real world ease of use for individuals requiring vision correction when wearing AR smart glasses and HMD solutions. The Company has already begun demonstrating this capability to its potential OEM customers. This solution can be produced in high volume at a competitive cost and is in addition to the elimination of external eye glow via its recently introduced Incognito waveguide technology, two critical advancements to the ultimate success and acceptance of AR smart glasses.

Key Points: 
  • Vuzix is currently in the process of establishing the infrastructure to support the production of prescription-based integrated waveguide lens assemblies with a roadmap set to scale production substantially thereafter.
  • Multiple patents and patents pending are in place related to system processes and integrating scripts or optical power for smart glasses eyewear.
  • Vision correction will initially support a range of +2D to -8D diopters but will ultimately support any prescription.
  • Given that 64% of the global population requires some level of vision correction, we believe the opportunity is significant."

FlexEnable launches flexible active optics evaluation kits for AR and VR

Retrieved on: 
Tuesday, January 30, 2024
VR, OTFT, SPIE, Dioptre, FlexEnable, Electronics, 3D, OEM, Immersion, Telescopic sight

CAMBRIDGE, England, Jan. 30, 2024 /PRNewswire/ -- FlexEnable , the leader in the development and production of flexible organic electronics for active optics and displays, today announces the launch of optical evaluation kits for AR and VR devices.

Key Points: 
  • CAMBRIDGE, England, Jan. 30, 2024 /PRNewswire/ -- FlexEnable , the leader in the development and production of flexible organic electronics for active optics and displays, today announces the launch of optical evaluation kits for AR and VR devices.
  • The kits include ambient dimming and tunable lens film modules made using FlexEnable's flexible liquid crystal (LC) technology.
  • The evaluation kits are initially available to selected strategic partners who wish to evaluate FlexEnable's breakthrough technology for integration into new products.
  • FlexEnable will be exhibiting at SPIE AR VR MR in San Francisco on 30-31 January 2024.

FlexEnable launches flexible active optics evaluation kits for AR and VR

Retrieved on: 
Tuesday, January 30, 2024
VR, OTFT, SPIE, Dioptre, FlexEnable, Electronics, 3D, OEM, Immersion, Telescopic sight

CAMBRIDGE, England , Jan. 30, 2024 /PRNewswire/ -- FlexEnable , the leader in the development and production of flexible organic electronics for active optics and displays, today announces the launch of optical evaluation kits for AR and VR devices.

Key Points: 
  • CAMBRIDGE, England , Jan. 30, 2024 /PRNewswire/ -- FlexEnable , the leader in the development and production of flexible organic electronics for active optics and displays, today announces the launch of optical evaluation kits for AR and VR devices.
  • The kits include ambient dimming and tunable lens film modules made using FlexEnable's flexible liquid crystal (LC) technology.
  • The evaluation kits are initially available to selected strategic partners who wish to evaluate FlexEnable's breakthrough technology for integration into new products.
  • FlexEnable will be exhibiting at SPIE AR VR MR in San Francisco on 30-31 January 2024.

STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision

Retrieved on: 
Tuesday, January 23, 2024
General Health, Surgery, Medical Devices, Health, Optical, MD, Ophthalmology, PIB, Contact, ASCRS, Presbyopia, EVO, Multimedia, Astigmatism, Near-sightedness, Society, Dioptre, Quality, PRK, Marketing, Surgeon, Lens, ICL, Refractive surgery, Nave, Cataract

View the full release here: https://www.businesswire.com/news/home/20240123947715/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240123947715/en/
    STAAR Surgical and SharpeVision will collaborate on marketing and education activities to elevate awareness of EVO ICL and significantly increase availability of the lenses to all qualified patients in SharpeVision clinics.
  • STAAR Surgical will also provide additional practice development and clinical support.
  • “We are pleased to announce SharpeVision as a new partner under our U.S. Highway 93 go-to-market program initiated in October 2023.
  • Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery.

HTC VIVE Launches VIVE XR Elite Big Bundle Deal: A Game-Changing Offer for VR Enthusiasts

Retrieved on: 
Friday, September 1, 2023
Dioptre, IPD, Air guitar, Blog, HTC, USD, VR, VIVE, HTC Vive, Power, Virtual reality, XR, Green Hell (video game), FOV, Video game

SEATTLE, Sept. 1, 2023 /PRNewswire/ -- HTC VIVE, a trailblazer in the realm of virtual reality, is thrilled to introduce the VIVE XR Elite Big Bundle Deal.

Key Points: 
  • SEATTLE, Sept. 1, 2023 /PRNewswire/ -- HTC VIVE, a trailblazer in the realm of virtual reality, is thrilled to introduce the VIVE XR Elite Big Bundle Deal.
  • With cutting-edge VR hardware, captivating games, and a VIVE Streaming Cable, the Big Bundle Deal provides great value for VR gamers who demand the best.
  • VIVE Streaming Cable: Valued at USD $79, the VIVE Streaming Cable enables high-fidelity, low-latency PC VR streaming.
  • VIVE XR Elite – HTC VIVE's Powerful, Lightweight XR Headset:
    VIVE XR Elite is the latest cutting-edge headset from HTC VIVE, offering immersive XR experiences in a lightweight, compact form factor.

SightMD NJ Surgeon performs first implantation of this revolutionary intraocular lens in New Jersey

Retrieved on: 
Tuesday, April 25, 2023
Retina, Cornea, Surgeon, Dioptre, Cataract, Eye, Hope, Astigmatism, MD, Patient, Emmetropia, Intraocular lens, FDA, GLARE, Dentistry, Telescopic sight, Aphera, IOL

HAUPPAUGE, N.Y., April 25, 2023 /PRNewswire-PRWeb/ -- A dramatically New design IntraOcular Lens called the Apthera IC-8 was approved by the FDA and released in Jan of 2023 and we are excited to announce that the first implantation of this revolutionary intraocular lens in New Jersey was performed by SightMD Ophthalmic Surgeon Omar F. Almallah, MD last week.

Key Points: 
  • The IC-8 Apthera Intraocular Lens (IOL) is an artificial lens implanted in the eye of adult patients.
  • The lens is intended to provide vision correction after the eye's natural lens is removed because it has become cloudy (cataract).
  • The IC-8 Apthera IOL is the first small aperture lens that delivers extended depth of focus through its distinctive wavefront-filtering design.
  • The IC-8 Apthera lens is an extended depth of focus intraocular lens.

The D. E. Shaw Group Raises Combined $1.1 Billion for Two New Funds Focused on Private Market Opportunities

Retrieved on: 
Tuesday, February 14, 2023
Investment, Private credit, Risk management, Data analysis, Voltaic, History, Dioptre, Financial services, Security (finance), Bank

NEW YORK, Feb. 14, 2023 /PRNewswire/ -- The D. E. Shaw group, a global investment and technology development firm, today announced that it has raised $1.1 billion in combined commitments for two new funds, D. E. Shaw Voltaic Fund and D. E. Shaw Diopter Fund, focused on private market investment opportunities. The firm's entities, principals, and employees contributed more than $150 million in total to the new funds. These fundraises represent the latest milestone in the long-term buildout of the firm's private investing strategies.

Key Points: 
  • These fundraises represent the latest milestone in the long-term buildout of the firm's private investing strategies.
  • Voltaic, which received more than $450 million in capital commitments, is overseen by the D. E. Shaw group's Fundamental Equities team.
  • The D. E. Shaw group has invested in private markets for much of its history, although Voltaic is the firm's first standalone fund dedicated to private equity investments.
  • The D. E. Shaw group raised its first private credit fund in 2008, and since 2012 it has raised—inclusive of Diopter—more than $3.5 billion focused on the asset class.

Harvard Eye Associates is the First to Implant the New IC-8® Apthera™ Intraocular Lens in Orange County, CA

Retrieved on: 
Monday, February 6, 2023
Patient, Light, Dioptre, Cataract, Eye, Astigmatism, Retina, Photography, U.S. FDA, Clinical trial, FDA, RK, Camera, IOL

"This new lens represents a major new offering for people undergoing cataract surgery because it can help them see a range of vision, which previous single-focus were unable to do. Furthermore, this lens may be particularly appropriate for people who have had previous eye surgery like Lasik or RK. It's based on a very simple and well-understood concept from photography--that a small opening in a lens can increase depth of field greatly. Our experience implanting this lens in the studies that led to FDA approval was extremely positive, and we know it will be popular with patients," said Dr. John Hovanesian, one of the board-certified cataract surgeons at Harvard Eye Associates.

Key Points: 
  • LAGUNA HILLS, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Eye Associates, a multi-specialty ophthalmology practice, implanted the first IC-8® Apthera™ intraocular lens (IOL) in Orange County, CA, since U.S. FDA approval of this new implant.
  • The FDA-approved Apthera™ IOL has a FilterRing™ component that creates a small aperture to adjust the amount of light entering the eye.
  • The Apthera™ IOL is intended for use in one eye with a monofocal or monofocal toric IOL in the fellow eye.
  • Patients interested in cataract surgery with the Apthera™ IOL may contact Harvard Eye by calling 949-951-2020 or visiting harvardeye.com .

Bausch + Lomb Acquires AcuFocus, Inc.

Retrieved on: 
Tuesday, January 17, 2023
Medical Supplies, Medical Devices, Health, Surgery, General Health, Optical, Cataract, Severe cognitive impairment, Ageing, Presbyopia, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Food, Growth, EDOF, Patient, Bausch & Lomb, Physician, Dioptre, Astigmatism, Multimedia, Telescopic sight, Pharmaceutical industry, IOL

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.
  • Known as the IC-8 IOL in global markets, this IOL is available in select markets across Europe, as well as in Australia, New Zealand and Singapore.
  • Some available presbyopia-correcting IOLs have complex optics that split, shift or stretch light to provide clear vision at more than one discrete focal point.
  • “With its extensive development footprint and renowned commercial expertise, we believe Bausch + Lomb is best positioned to educate physicians about the IC-8 Apthera lens, and ultimately, ensure more cataract patients have access to this new IOL.”

Professional Basketball Player Max Strus Kicks Off New Season With Upgraded Vision From Life-Changing EVO ICL Lenses

Retrieved on: 
Wednesday, October 12, 2022
Sports, Medical Supplies, Licensing (Sports), Health, Marketing, Optical, Advertising, Communications, Medical Devices, Surgery, Basketball, Quality, NASDAQ, Cornea, CEO, Myopia, Athlete, ASCRS, Refractive surgery, Intraocular lens, Iris, ICL, Cataract, Inflammation, Eye, American Society of Cataract and Refractive Surgery, Nave, Ophthalmology, Literature, FDA, Astigmatism, Glaucoma, Prevalence, Lens, Review, Society, Dioptre, Lens (anatomy), Security (finance), Multimedia, Nursing, Intention, U.S. Securities and Exchange Commission, Night vision, STAAR, Allergen, Education, Retinal implant, Partnership, Glasses, Learning, Awareness, Social media, EVO, Medical device, Telescopic sight, Health insurance, Borosilicate glass, Strus, LASIK, Life, Patient

View the full release here: https://www.businesswire.com/news/home/20221012005068/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221012005068/en/
    Max Strus, American professional basketball player, practices his on-court skills with sharper vision from EVO ICL - a new FDA-approved vision correction lens designed for the correction/reduction of myopia (nearsightedness) and astigmatism.
  • Recently, Strus had EVO lenses implanted by his doctor to upgrade his vision and break free from the hassles of eyeglasses and contact lenses.
  • Following the EVO procedure, he went from struggling with the hassles of contact lenses, both on and off the court, to having clear vision better than 20/20.
  • Starting this month, Max Strus will share his journey in national and social media campaigns which will later be expanded globally.